Hensin Tsao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3450788/publications.pdf

Version: 2024-02-01

114 papers	7,529 citations	76326 40 h-index	53230 85 g-index
116 all docs	116 docs citations	116 times ranked	9524 citing authors

#	Article	IF	Citations
1	Management of Cutaneous Melanoma. New England Journal of Medicine, 2004, 351, 998-1012.	27.0	735
2	Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155.	5.9	415
3	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103.	27.8	413
4	Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma. Journal of Investigative Dermatology, 2004, 122, 337-341.	0.7	411
5	Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250.	1.2	400
6	High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Research, 2006, 66, 9818-9828.	0.9	373
7	The Transformation Rate of Moles (Melanocytic Nevi) Into Cutaneous Melanoma. Archives of Dermatology, 2003, 139, 282.	1.4	282
8	Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene, 1998, 16, 3397-3402.	5.9	224
9	Cutaneous Melanomas Associated With Nevi. Archives of Dermatology, 2003, 139, 1620.	1.4	224
10	Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Human Mutation, 2007, 28, 578-588.	2.5	222
11	Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Research, 2000, 60, 1800-4.	0.9	185
12	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
13	Hereditary melanoma: Update on syndromes and management. Journal of the American Academy of Dermatology, 2016, 74, 395-407.	1.2	158
14	Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside. Journal of Investigative Dermatology, 2008, 128, 2575-2595.	0.7	157
15	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
16	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-2370.	4.1	142
17	Genetics of melanocytic nevi. Pigment Cell and Melanoma Research, 2015, 28, 661-672.	3.3	135
18	Gender Disparity and Mutation Burden in Metastatic Melanoma. Journal of the National Cancer Institute, 2015, 107, djv221.	6.3	114

#	Article	IF	Citations
19	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287.	9.4	107
20	PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. Journal of the American Academy of Dermatology, 2003, 49, 865-872.	1.2	103
21	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	7.0	96
22	Somatic driver mutations in melanoma. Cancer, 2017, 123, 2104-2117.	4.1	96
23	Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. Journal of Investigative Dermatology, 2006, 126, 2490-2506.	0.7	86
24	Genotypic and Phenotypic Features of BAP1 Cancer Syndrome. JAMA Dermatology, 2017, 153, 999.	4.1	86
25	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€“Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273.	9.4	82
26	A recurrent germline <scp>BAP1</scp> mutation and extension of the <scp>BAP1</scp> tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 2015, 88, 267-272.	2.0	81
27	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
28	MITF Modulates Therapeutic Resistance through EGFR Signaling. Journal of Investigative Dermatology, 2015, 135, 1863-1872.	0.7	76
29	Outcome of patients with de novo versus nevus-associated melanoma. Journal of the American Academy of Dermatology, 2015, 72, 54-58.	1.2	71
30	KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Medical Journal, 2020, 61, 562.	2.2	67
31	p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. Journal of Investigative Dermatology, 2012, 132, 356-364.	0.7	66
32	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7.	6.4	66
33	Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer, 2001, 91, 874-880.	4.1	61
34	Hereditary melanoma: Update on syndromes and management. Journal of the American Academy of Dermatology, 2016, 74, 411-420.	1.2	60
35	Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Research, 1998, 58, 109-13.	0.9	56
36	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53

#	Article	IF	Citations
37	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. Journal of Investigative Dermatology, 2016, 136, 1002-1011.	0.7	51
38	Burden of unique and low prevalence somatic mutations correlates with cancer survival. Scientific Reports, 2019, 9, 4848.	3.3	49
39	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal of Investigative Dermatology, 2018, 138, 1582-1590.	0.7	46
40	The first 30Âyears of the American Academy of Dermatology skin cancer screening program: 1985-2014. Journal of the American Academy of Dermatology, 2018, 79, 884-891.e3.	1.2	46
41	Early Detection of Asymptomatic Pulmonary Melanoma Metastases by RoutineChest Radiographs Is Not Associated With Improved Survival. Archives of Dermatology, 2004, 140, 67-70.	1.4	45
42	Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1â€“Transduced Dendritic Cell Vaccine for Metastatic Melanoma. Archives of Dermatology, 2002, 138, 799-802.	1.4	42
43	Melanoma: Clinical Features and Genomic Insights. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015388-a015388.	6.2	42
44	Hypoxia and HIF-1Î± Regulate Collagen Production in Keloids. Journal of Investigative Dermatology, 2020, 140, 2157-2165.	0.7	39
45	A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Archives of Dermatology, 2001, 137, 325-30.	1.4	39
46	BRCA1â€associated protein (BAP1)â€inactivated melanocytic tumors. Journal of Cutaneous Pathology, 2019, 46, 965-972.	1.3	38
47	Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Research, 1999, 59, 172-4.	0.9	34
48	Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth. Clinical Cancer Research, 2013, 19, 4383-4391.	7.0	33
49	In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Scientific Reports, 2016, 6, 37986.	3.3	33
50	Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. Journal of the National Cancer Institute, 2017, 109, .	6.3	32
51	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-70.	4.1	32
52	The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis. Journal of the American Academy of Dermatology, 2014, 71, 1071-1076.	1.2	31
53	BAP1 Has a Survival Role in Cutaneous Melanoma. Journal of Investigative Dermatology, 2015, 135, 1089-1097.	0.7	31
54	Cutaneous melanoma in women. International Journal of Women's Dermatology, 2017, 3, S11-S15.	2.0	29

#	Article	IF	Citations
55	Contrasting features of childhood and adolescent melanomas. Pediatric Dermatology, 2018, 35, 354-360.	0.9	26
56	Melanocytes Are Selectively Vulnerable to UVA-Mediated Bystander Oxidative Signaling. Journal of Investigative Dermatology, 2014, 134, 1083-1090.	0.7	24
57	Melanoma Treatment Update. Dermatologic Clinics, 2005, 23, 323-333.	1.7	23
58	Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas. JAMA Dermatology, 2019, 155, 211.	4.1	22
59	Epidermal, Sebaceous, and Melanocytic Nevoid Proliferations Are Spectrums of Mosaic RASopathies. Journal of Investigative Dermatology, 2014, 134, 2493-2496.	0.7	21
60	Clinical spectrum of cutaneous melanoma morphology. Journal of the American Academy of Dermatology, 2019, 80, 178-188.e3.	1.2	21
61	Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services. Dermatologic Clinics, 2021, 39, 627-637.	1.7	21
62	Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel GermlineBAP1Mutation. JAMA Dermatology, 2015, 151, 1235.	4.1	20
63	Cancer risks associated with the germline MITF(E318K) variant. Scientific Reports, 2020, 10, 17051.	3.3	20
64	Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 60-67.	1.6	20
65	Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. Genetics in Medicine, 2021, 23, 2087-2095.	2.4	19
66	Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. JAMA - Journal of the American Medical Association, 2016, 316, 398.	7.4	18
67	Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines. , 1997, 72, 337-339.		16
68	Classifying Melanoma by TERT Promoter Mutational Status. Journal of Investigative Dermatology, 2020, 140, 390-394.e1.	0.7	16
69	A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. Journal of the American Academy of Dermatology, 2002, 46, 55-61.	1.2	15
70	Cutaneous melanoma in women. International Journal of Women's Dermatology, 2015, 1, 21-25.	2.0	12
71	Targeted Therapies in Melanoma: Translational Research at Its Finest. Journal of Investigative Dermatology, 2015, 135, 1929-1933.	0.7	12
72	Recent Advances in Melanoma and Melanocyte Biology. Journal of Investigative Dermatology, 2017, 137, 557-560.	0.7	12

#	Article	IF	Citations
73	Melanoma genomics: a stateâ€ofâ€theâ€art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281.	1.5	12
74	Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene, 2019, 38, 3504-3520.	5.9	11
75	Update on familial cancer syndromes and the skin. Journal of the American Academy of Dermatology, 2000, 42, 939-69; quiz 970-2.	1.2	11
76	Defining Clonal Color in Fluorescent Multi-Clonal Tracking. Scientific Reports, 2016, 6, 24303.	3.3	10
77	Betaâ€catenin causes fibrotic changes in the extracellular matrix via upregulation of collagen I transcription. British Journal of Dermatology, 2017, 177, 312-315.	1.5	10
78	Selective uveal melanoma inhibition with calcium channel blockade. International Journal of Oncology, 2019, 55, 1090-1096.	3.3	10
79	Case 7-2004. New England Journal of Medicine, 2004, 350, 924-932.	27.0	9
80	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465.	4.3	9
81	A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel, Switzerland), 2019, 6, 255-259.	1.5	9
82	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. Journal of Investigative Dermatology, 2021, 141, 1317-1324.e1.	0.7	9
83	A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biology and Therapy, 2016, 17, 778-784.	3.4	8
84	Surgical delay and mortality for primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1089-1091.	1.2	8
85	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. Journal of Investigative Dermatology, 2021, 141, 2018-2027.e4.	0.7	8
86	Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SpotMe screening program participants during 2009-2010. Journal of the American Academy of Dermatology, 2023, 88, 60-70.	1.2	6
87	Consensus, Controversy, and Conversations About Gene Expression Profiling in Melanoma. JAMA Dermatology, 2020, 156, 949.	4.1	6
88	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. American Journal of Cancer Research, 2017, 7, 134-138.	1.4	6
89	Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. BMC Cancer, 2021, 21, 371.	2.6	5
90	Ultraâ€late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-2370.	4.1	5

#	Article	IF	Citations
91	Commentary: Molecular testing in melanoma. Journal of the American Academy of Dermatology, 2014, 70, 863-870.	1.2	4
92	New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Neviâ€"Highlighting the Keratinocyte-Melanocyte Relationship. Journal of Investigative Dermatology, 2016, 136, 1933-1935.	0.7	4
93	Caseâ€"control analysis identifies shared properties of rare germline variation in cancer predisposing genes. European Journal of Human Genetics, 2019, 27, 824-828.	2.8	4
94	The spectrum of morphologic patterns of nodular melanoma: a study of the International Dermoscopy Society. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e762-e765.	2.4	4
95	Recognition, Staging, and Management of Melanoma. Medical Clinics of North America, 2021, 105, 643-661.	2.5	4
96	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Management, 2015, 2, 133-147.	0.5	3
97	Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation. American Journal of Dermatopathology, 2018, 40, 378-382.	0.6	3
98	Number needed to screen for presumptive screening diagnoses among first-time SPOTme screening participants (1992-2010). Journal of the American Academy of Dermatology, 2020, 82, 233-234.	1.2	3
99	Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. Journal of Investigative Dermatology, 2022, 142, 1413-1424.e6.	0.7	3
100	Melanoma-associated naevi: precursors or coincidence?. British Journal of Dermatology, 2015, 173, 633-634.	1.5	2
101	Epidemiology of Melanoma. , 2017, , 591-611.		2
102	The SNPs of RAF. Journal of Investigative Dermatology, 2005, 125, xiv-xv.	0.7	1
103	Unsupervised Phenotype-Based Clustering of Clinicopathologic Features in Cutaneous Melanoma. JID Innovations, 2021, 1, 100047.	2.4	1
104	Epithelioid Sarcoma Presenting as a Benign Foot Ulcer. Journal of Cutaneous Medicine and Surgery, 1997, 1, 232-234.	1.2	0
105	Case 30-2010. New England Journal of Medicine, 2010, 363, 1352-1360.	27.0	0
106	Opening the melanoma black box. British Journal of Dermatology, 2014, 170, 9-10.	1.5	0
107	Concerns About Presence of a Wild-TypeBAP1Allele in Absence of Nuclear Protein Expressionâ€"Reply. JAMA Dermatology, 2015, 151, 1266.	4.1	0
108	Reply to: â€œThe ABCDs of melanomaâ€"A complicated morphologic message not intended for the general publicâ€. Journal of the American Academy of Dermatology, 2015, 73, e61.	1.2	0

#	Article	IF	Citations
109	Reply to: â€œThe absence of multiple atypical nevi in germline CDKN2A mutationsâ€• Journal of the American Academy of Dermatology, 2016, 75, e159.	1.2	0
110	Introduction to JIDâ€™s Landmarks inÂtheÂMolecular Revolution. Journal of Investigative Dermatology, 2017, 137, 996.	0.7	0
111	A geographically based cross-sectional analysis of SPOT me skin cancer screening data. Journal of the American Academy of Dermatology, 2021, 84, 809-810.e3.	1.2	0
112	Melanoma medicine in the new millennium. British Journal of Dermatology, 2021, 185, 239-240.	1.5	0
113	Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma. , 2021, , .		0
114	American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Targets of genetic injury in cutaneous melanoma. Journal of the American Academy of Dermatology, 1999, 41, 459-61.	1.2	0